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Terumo wire. PDA Sheath was passed through RA, RV and then into
Aorta with Kissing technique sheath was positioned in LV. PDA device
was loaded in sheath. Device was positioned on LV side ﬁrst and then
on RV side. Position was checked on 2D-Echo which was found to be
accurate. Wire and catheter was removed. Post procedure treatment
with steroids was advised as per standard treatment. Antiplatelet
aspirin was recommended for one month.
RESULTS Procedure was done successfully in 66 without any com-
plications. In 15 cases Transient BBB was developed on during pro-
cedure. In 1 case complication of CHB occurred during procedure in
which temporary pace maker (TPM) was implanted for 3 days. In
another case, complication of CHB occurred in ICU after 3 hours in
which TPM was done for 2 days. In 2 cases device was embolized, 1
device successfully retrieved with help of the basket snare and
continued procedure with bigger size device, another 1 case went to
surgery. 1 case of death was observed on 5thday, which was due to
stroke. At 1 year follow up no shunt was noted in ECHO and ECG
remained same with no additional conditional defect.
CONCLUSION Transcatheter closure is safe and efﬁcacious in selected
cases of perimembranous and muscular VSD using PDA device. Tras-
catheter closure of ventricular septal defect using PDA devices is
gaining acceptance in selected cases as compare to surgical closure
which is associated with morbidity and mortality. Potential advan-
tages of the transcatheter closure over conventional surgery include a
smaller incision, shorter stay and fewer complications.
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BACKGROUND Transcatheter closure of patent ductus arteriosus
(PDA) is a simple, safe and effective procedure, being done
throughout the world. Since the ﬁrst use of Ivalon plugin 1967 (1), no
other shunt lesion has seen so much advancement in the development
of device technology as PDA, the latest being the second generation
Amplatzer vascular plugs (St Jude Medical, Plymouth, IN, USA).
However, the maximum sizes available amongst the commonly used
devices are 16/14 mm for Amplatzer duct occluder I (AGA Medical
corporation, Golden Valley, MN, USA), 22mm for Amplatzer vascular
plug II and 24/22 mm for Cera PDA occluder (Lifetech Scientiﬁc,
Shenzhen, China).
In developing countries, many patients with large PDA present late
in life. In the absence of large size devices, the only option left for
these patients is surgical ligation. Here we report four patients with
large PDA, and their transcatheter closure with custom made large
PDA occluder or muscular ventricular septal defect (VSD) occluder.
We are presenting six cases of large PDA measuring 14-16 mm in
young adolescent & adult where in in four cases were closed with
30/28 mm PDA from life tech china & in two cases 24mm muscular
VSD device was used. PDA device used was two times the size of PDA.
In two children on 12 years PDA 30/28 was too large & was changed to
24 mm muscular VSD device successfully.
CONCLUSIONS Patients with large PDA diagnosed late in life are
commonly seen in developing countries. Dedicated custom-made
transcatheter devices can be used successfully for transcatheter
closure of these PDA without signiﬁcant complications instead of
using expensive muscular VSD occluders or surgery.
METHODS Case 1
A 16 years old patient was referred with an incidentally detected
murmur. On examination, she had a continuous murmur in the left
ﬁrst and second intercostal spaces. Echocardiography showed a large
PDA with enlarged left atrium (LA) and left ventricle (LV) and pre-
served left ventricular systolic function. After an informed consent,
she was taken up for cardiac catheterization and device closure. Both
femoral artery and vein were accessed after giving local anaesthesia.
Hemodynamic study revealed pulmonary artery systolic pressure
(PSAP) of 48 mmHg, systemic systolic pressure of 130 mmHg, Qp/Qs of
2.83 and PVR/SVR of 0.09. Descending aortogram was done using a 6F
pigtail catheter (Cordis corporation, Florida, USA) and ductus size was
measured to be 15 mm in lateral view.After crossing the PDA from pulmonary artery side using a Multi-
purpose catheter (Cordis corporation, Florida, USA), a 0.035 inch, and
260cm Amplatzer extra stiff guide wire (AGA Medical Corporation,
Golden Valley, MN, USA) was introduced. A 14F cook delivery sheath
(Cook, Bloomington, IN) was inserted over the guidewire and a 24 mm
atrial septal defect occluder (AGA Medical corporation, Golden Valley,
MN, USA) was positioned across the PDA. A check angiogram showed
substantial ﬂow across the device.
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custom made Cera PDA occluder (Lifetech Scientiﬁc, Shenzhen,
China). In the second setting, using the same hardware, a custom
made 30/28 mm Cera PDA occluder was positioned across the PDA. A
descending aortogram, done 15 minutes after positioning the device,
showed some ﬂow across the device.
A repeat angiogram, done 30 minutes later showed markedly
reduced ﬂow across the PDA. The device was released at this time,
under ﬂuoroscopic guidance.Echocardiography done next day showed no ﬂow across the PDA.
RESULTS Six patients with large PDA measuring 14-16 mm were taken
up for percutaneous device closure. After failed attempt with 24 mm
ASD device& 16 mm AGA PDA device in ﬁrst cases all four cases were
closed successfully with life tech 30/28 mm PDA device closure. In two
cases children between 12-14 yrs PDA device of 30/28 mm was too big
to obstruct aorta and was replaced with 24 mm muscular VSD device
successfully. Two patients have had follow up cath angio which
conﬁrmed low pa pressure & no obstruction of aorta or LPA.
CONCLUSION In selected cases of large PDA measuring 14-16 mm
1) PDA device with life tech 30/28 mm is successful (PDA device is
two times the size of PDA)
2) 30/28 mm PDA is too large for children of 12 years & below & it
results in obstruction of aorta
3) this is more cost effective simple than surgery
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BACKGROUND The ResoluteTM zotarolimus-eluting stent (R-ZES)
demonstrates favorable outcomes in the treatment of coronary lesions
across a range of patient and lesion complexity. However, limited
long-term data is available on the treatment of long lesions. The
RESOLUTE 38-mm substudy of the RESOLUTE Global Clinical Program
was prospectively designed to include patients requiring treatment of
de novo lesions in native coronary arteries with a 38-mm length
R-ZES.
METHODS The RESOLUTE 38-mm substudy includes patients from
the RESOLUTE US (R-US) and RESOLUTE Asia (R-Asia) prospective,
observational, nonrandomized, multicenter trials that enrolled pa-
tients from 29 sites across the United States (U.S.) and 17 sites across
Asia. Patients enrolled in these trials who received at least one 38-mm
R-ZES in a lesion 35 mm in length and reference vessel diameter of
3.0 to 4.2 mm with up to two lesions (in separate vessels) were
included in the 38-mm substudy. Target lesion failure (TLF) was
deﬁned as the composite of cardiac death (CD), target vessel
myocardial infarction (TV-MI), or clinically driven target lesion
revascularization (TLR). The RESOLUTE 38-mm substudy was a pre-
speciﬁed analysis; a post hoc analysis by geography (Asia vs. US) was
also conducted.
RESULTS A total of 223 patients (114 in R-US and 109 in R-Asia) were
enrolled. Mean lesion length was 25.2  8.8 mm (24.2  9.1 in R-US vs.
26.3  8.5 in R-Asia, p¼0.059). Compared with R-Asia patients, R-US
patients were older (65  10 mm vs. 57  10 mm, p<0.001), and more
likely to have diabetes mellitus (44% vs. 31%, p¼0.051) and insulin
dependent diabetes mellitus (15% vs. 6%, 0.021). Three-year follow-
up was available in 221 (99.1%) patients demonstrating a low inci-
dence of adverse clinical events (Figure, left). There was furthermore
no difference at 3 years in the rates of TLR, CD, or TV-MI between
R-Asia and R-US; however, TLF was lower in R-Asia (Figure, right).
CONCLUSION The 38-mm length R-ZES was associated with excellent
and sustained clinical outcomes during long-term follow-up. Patients
enrolled in Asia appeared to be less complex than those enrolled in
the U.S., but clinical events remained similar other than for TLF.
